MasterMeditech Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$7.07M
- Investors
-
9
MasterMeditech General Information
Description
Developer of pharmaceutical chemical technology designed to discover new drug candidates. The company's technology uses protein structure identification and pharmaceutical chemistry technology that focuses on genomics and cell biology, enabling doctors to get effective drugs to treat their patients with advanced medical development.
Contact Information
Website
www.mastermeditech.co.krCorporate Office
- Room 302, 3rd floor
- 38, Magokjungang 8-ro, 1-gil, Gangseo-gu
- Seoul
- South Korea
Corporate Office
- Room 302, 3rd floor
- 38, Magokjungang 8-ro, 1-gil, Gangseo-gu
- Seoul
- South Korea
MasterMeditech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 29-Mar-2021 | $7.07M | Completed | Clinical Trials - Phase 1 | ||
| 1. Seed Round | 31-Oct-2019 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
MasterMeditech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MasterMeditech Patents
MasterMeditech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025071160-A1 | Idelalisib-containing solid preparation for oral administration, and preparation method therefor | Inactive | 25-Sep-2023 | ||
| US-10463669-B2 | Composition for treating or preventing liver cancer | Active | 15-Feb-2016 | ||
| US-20190160073-A1 | Composition for treating or preventing liver cancer | Active | 15-Feb-2016 | A61K31/52 |
MasterMeditech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MasterMeditech Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Foresight-cape bio | Corporate Development | Minority | ||
| Huons Global | Corporation | Minority | ||
| innocence. | Corporation | Minority | ||
| Mindspace | VC-Backed Company | Minority | ||
| Pharmbio Korea | Corporation | Minority |
MasterMeditech FAQs
-
When was MasterMeditech founded?
MasterMeditech was founded in 2019.
-
Where is MasterMeditech headquartered?
MasterMeditech is headquartered in Seoul, South Korea.
-
What is the size of MasterMeditech?
MasterMeditech has 7 total employees.
-
What industry is MasterMeditech in?
MasterMeditech’s primary industry is Drug Discovery.
-
Is MasterMeditech a private or public company?
MasterMeditech is a Private company.
-
What is MasterMeditech’s current revenue?
The current revenue for MasterMeditech is .
-
How much funding has MasterMeditech raised over time?
MasterMeditech has raised $7.49M.
-
Who are MasterMeditech’s investors?
Foresight-cape bio, Huons Global, innocence., Mindspace, and Pharmbio Korea are 5 of 9 investors who have invested in MasterMeditech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
